Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3297 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2D6CYP1A2CYP2C9NFKB1 | |
| SCHEMBL206710 | 1.00 | CYP3A4 (0.44) | CYP3A4CYP2D6CYP1A2CYP2C9NFKB1 | |
| Hydrochloric Acid SCHEMBL975844 | 0.97 | LMNA (0.46) | CYP3A4CYP2D6CYP1A2CYP2C9NFKB1 | |
| Hydrochloric Acid SCHEMBL14744098 | 0.97 | LMNA (0.46) | CYP3A4CYP2D6CYP1A2CYP2C9NFKB1 | |
| Hydrochloric Acid SCHEMBL320242 | 0.97 | LMNA (0.46) | CYP3A4CYP2D6CYP1A2CYP2C9NFKB1 | |
| Hydrochloric Acid SCHEMBL214837 | 0.97 | LMNA (0.46) | CYP3A4CYP2D6CYP1A2CYP2C9NFKB1 | |
| Hydrochloric Acid SCHEMBL23455679 | 0.95 | CYP3A4 (0.42) | CYP3A4CYP2D6CYP1A2CYP2C9NFKB1 | |
| Hydrochloric Acid SCHEMBL21612238 | 0.95 | CYP3A4 (0.42) | CYP3A4CYP2D6CYP1A2CYP2C9NFKB1 | |
| Acetic Acid SCHEMBL5168057 | 0.93 | CYP3A4 (0.41) | CYP3A4CYP2D6CYP1A2CYP2C9NFKB1 | |
| SCHEMBL7447781 | 0.93 | CYP3A4 (0.41) | CYP3A4CYP2D6CYP1A2CYP2C9NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | IMMUNOGEN INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | MARS, INCORPORATED (US) | 2026-04-30 | — | — | US | disclosed |
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | IMMUNOGEN, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-4593631-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | Mars, Incorporated (US) | 2025-08-06 | — | — | EP | disclosed |
| CN-119968127-A | Animal food compositions with improved palatability and customizable properties and methods of making the same | 玛氏公司 | 2025-05-09 | — | — | CN | disclosed |
| WO-2025056012-A1 | NEUTROPHIL ELASTASE INHIBITOR AND USE THEREOF | 上海壹迪生物技术有限公司 | 2025-03-20 | — | — | WO | disclosed |
| CN-119638624-A | Neutrophil elastase inhibitor and application thereof | 上海壹迪生物技术有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-3612524-B1 | 6-PYRIMIDIN-ISOINDOLE DERIVATIVE AS ERK1/2 INHIBITOR | OTSUKA PHARMA CO LTD (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-114206884-B | Thienopyrimidine derivatives as ACC inhibitors and use thereof | 吉利德科学公司 | 2024-07-12 | — | — | CN | disclosed |
| US-12030873-B2 | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| US-5965566-A | A WATER SOLUBLE BIOLOGICAL ACTIVE DRUG CONJUGATED WITH POLYOXYETHYLENE GLYCOL THROUGH A HYDROLYZABLE ESTER LINKAGING SPACER; CONTROLLED RELEASE PROPERTIES | ENZON, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0939760-A2 | 1-THIOGALACTOSE DERIVATIVES | SYNSORB Biotech Inc. (CA) | 1999-09-08 | — | — | EP | disclosed |
| EP-0938492-A1 | COMBINATORIAL SYNTHESIS OF CARBOHYDRATE LIBRARIES | SYNSORB Biotech Inc. (CA) | 1999-09-01 | — | — | EP | disclosed |
| CN-1225360-A | Substituted imidazolidine derivatives, their prepn., their use and pharmaceutical prepn. comprising them | HOECHST MARION ROUSSEL DE GMBH (DE) | 1999-08-11 | — | — | CN | disclosed |
| EP-0915086-A1 | PHENYLSULFONAMIDE DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 1999-05-12 | — | — | EP | disclosed |
| US-5840900-A | POLYETHERS, POLYAMIDE POLYMERS WITH PRODRUGS | ENZON, INC. (US) | 1998-11-24 | — | — | US | disclosed |
| WO-1998022487-A1 | COMBINATORIAL SYNTHESIS OF CARBOHYDRATE LIBRARIES | SYNSORB BIOTECH, INC. (CA) | 1998-05-28 | — | — | WO | disclosed |
| WO-1998021221-A2 | 1-THIOGALACTOSE DERIVATIVES | SYNSORB BIOTECH, INC. (CA) | 1998-05-22 | — | — | WO | disclosed |
| CN-1125575-A | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 1996-07-03 | — | — | CN | disclosed |
| EP-0697408-A1 | 1 substituted-phenyl-oxazolidene-2-one derivatives and their use as adhesion-receptor antagonists | MERCK PATENT GmbH (DE) | 1996-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390471-B2 | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | VIP, AREG, MIF | CYP3A4 4562/4885CYP2D6 4317/4885CYP1A2 4637/4885 |
| US-12030873-B2 | 6-pyrimidin-isoindole derivative as ERK1/2 inhibitor | MAPKAPK2, MAP4K2, MAPK1 | CYP3A4 2724/4885CYP2D6 1071/4885CYP1A2 1337/4885 |
| US-20260114475-A1 | ANIMAL FOOD COMPOSITIONS WITH IMPROVED PALATABILITY AND CUSTOMIZABILITY, AND METHODS FOR PREPARING THE SAME | PIGS, TAS2R13, CEL | CYP3A4 3591/4885CYP2D6 3169/4885CYP1A2 2937/4885 |
| US-20260124212-A1 | MAYTANSINOID DERIVATIVES WITH SELF-IMMOLATIVE PEPTIDE LINKERS AND CONJUGATES THEREOF | VEGFA, VIP, AREG | CYP3A4 4682/4885CYP2D6 2881/4885CYP1A2 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.